Compass Therapeutics merger with Trigr completed; Trigr had $99k cash, $15.8M deficit

Compass Therapeutics, Inc.

Trigr audited 2020: cash $99k, total liabilities $2.57M, net loss $2.11M, accumulated deficit $15.8M; going concern doubt.
Trigr unaudited Q1 2021: cash $4.3M, net income $5.6M from $7M licensing revenue to Elpiscience.
Merger consideration: 10.27M Compass shares at $4.90/share (~$50.3M) plus up to $9M earnout.
Trigr lead asset CTX-009 licensed to Elpiscience for Greater China; $7M upfront, up to $110M milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.